{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone%2Fprednisone&page=2", "query": { "intervention": "Abiraterone/prednisone", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 177, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone%2Fprednisone&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone%2Fprednisone&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T15:49:15.824Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01088529", "title": "Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "LHRHa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cougar Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 66, "start_date": "2009-12", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-05-15", "last_synced_at": "2026-10-04T15:49:15.824Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088529" }, { "nct_id": "NCT01393730", "title": "Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Dutasteride", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mary-Ellen Taplin, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2011-09", "completion_date": "2017-03-15", "has_results": true, "last_update_posted_date": "2018-03-15", "last_synced_at": "2026-10-04T15:49:15.824Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Seattle, Washington", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01393730" }, { "nct_id": "NCT04577833", "title": "A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Abiraterone Acetate (AA)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 136, "start_date": "2020-11-13", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-04T15:49:15.824Z", "location_count": 1, "location_summary": "West Valley City, Utah", "locations": [ { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04577833" }, { "nct_id": "NCT06952803", "title": "A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Saruparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abiraterone + Prednisolone/Prednisone", "type": "DRUG" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 700, "start_date": "2025-08-06", "completion_date": "2036-04-30", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-04T15:49:15.824Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06952803" }, { "nct_id": "NCT04628988", "title": "A Study of CC-90011 and Comparators in Participants With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "CC-90011", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 6, "start_date": "2021-07-28", "completion_date": "2023-05-26", "has_results": false, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-04T15:49:15.824Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04628988" }, { "nct_id": "NCT05288166", "title": "A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms", "Neoplasm Metastasis", "Urogenital Neoplasms", "Physiological Effects of Drugs", "Antineoplastic Agents", "Antineoplastic Agents, Hormonal", "Androgens", "Hormones", "Hormones, Hormone Substitutes, and Hormone Antagonists", "Abiraterone Acetate", "Steroid Synthesis Inhibitors", "Cytochrome P-450", "Enzyme Inhibitors", "Prednisone", "Prednisolone", "Cyclin-Dependent Kinase 4", "Cyclin-Dependent Kinase 6" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone or Prednisolone", "type": "DRUG" }, { "name": "Placebo for Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 925, "start_date": "2022-04-14", "completion_date": "2027-10", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-04T15:49:15.824Z", "location_count": 63, "location_summary": "Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more", "locations": [ { "city": "Prescott", "state": "Arizona" }, { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05288166" }, { "nct_id": "NCT07611110", "title": "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Deutenzalutamide", "type": "DRUG" }, { "name": "Radium-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 670, "start_date": "2026-05-04", "completion_date": "2030-06-06", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-04T15:49:15.824Z", "location_count": 26, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Duarte, California + 23 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07611110" }, { "nct_id": "NCT03732820", "title": "Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "olaparib", "type": "DRUG" }, { "name": "abiraterone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 895, "start_date": "2018-10-31", "completion_date": "2027-02-05", "has_results": true, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-04T15:49:15.824Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Clovis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03732820" }, { "nct_id": "NCT03298087", "title": "Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Newly Diagnosed Oligometastatic Prostate Cancer" ], "interventions": [ { "name": "radical prostatectomy", "type": "PROCEDURE" }, { "name": "stereotactic body radiotherapy", "type": "RADIATION" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "apalutamide", "type": "DRUG" }, { "name": "abiraterone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 28, "start_date": "2018-07-01", "completion_date": "2024-03-31", "has_results": true, "last_update_posted_date": "2025-08-01", "last_synced_at": "2026-10-04T15:49:15.824Z", "location_count": 3, "location_summary": "Long Beach, California • West Los Angeles, California • Richmond, Virginia", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "West Los Angeles", "state": "California" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03298087" }, { "nct_id": "NCT03833921", "title": "Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer Metastatic", "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Martha Mims", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 130, "start_date": "2019-05-23", "completion_date": "2038-04", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-04T15:49:15.824Z", "location_count": 3, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03833921" } ] }